Digital Therapeutics for MCI and Alzheimer's disease: A Regulatory Perspective - Highlights From The Clinical Trials on Alzheimer's Disease conference (CTAD)

被引：5
|
作者：
Shuren, J. [1 ]
Doraiswamy, P. M. [2 ]
机构：
[1] US FDA, Ctr Devices & Radiol Hlth CDRH, Silver Spring, MD USA
[2] Duke Univ, Sch Med, Psychiat & Geriatr, Durham, NC 27708 USA
来源：
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE | 2022年 / 9卷 / 02期
关键词：
D O I：
10.14283/jpad.2022.28
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：236 / 240
页数：5
相关论文
共 50 条
  • [1] Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
    J. Shuren
    P. M. Doraiswamy
    The Journal of Prevention of Alzheimer's Disease, 2022, 9 : 236 - 240
  • [2] CTAD international research conference: Clinical trials in Alzheimer’s disease
    S. Gauthier
    J. Touchon
    B. Vellas
    Z. Katchaturian
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 204 - 204
  • [3] CTAD INTERNATIONAL RESEARCH CONFERENCE: CLINICAL TRIALS IN ALZHEIMER'S DISEASE
    Touchon, J.
    Vellas, B.
    Katchaturian, Z.
    Gauthier, S.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (03): : 204 - 204
  • [4] What We Learn from the CTAD 2018 (Clinical Trials Alzheimer’s Disease)
    Bruno Vellas
    P. Aisen
    M. Weiner
    J. Touchon
    The Journal of Prevention of Alzheimer's Disease, 2018, 5 (4) : 214 - 215
  • [5] What We Learn from the CTAD 2018 (Clinical Trials Alzheimer's Disease)
    Vellas, B.
    Aisen, P.
    Weiner, M.
    Touchon, J.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (04): : 214 - 215
  • [6] Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
    Veitch, Dallas P.
    Weiner, Michael W.
    Aisen, Paul S.
    Beckett, Laurel A.
    Cairns, Nigel J.
    Green, Robert C.
    Harvey, Danielle
    Jack, Clifford R., Jr.
    Jagust, William
    Morris, John C.
    Petersen, Ronald C.
    Saykin, Andrew J.
    Shaw, Leslie M.
    Toga, Arthur W.
    Trojanowski, John Q.
    Aisen, Paul
    Weiner, Michael
    Petersen, Ronald
    Trojanowki, John Q.
    Toga, Arthur W.
    Beckett, Laurel
    Morris, John
    Khachaturian, Zaven
    Sorensen, Greg
    Carrillo, Maria
    Kuller, Lew
    Raichle, Marc
    Paul, Steven
    Davies, Peter
    Fillit, Howard
    Hefti, Franz
    Holtzman, David
    Mesulam, M. Marcel
    Potter, William
    Snyder, Peter
    Montine, Tom
    Jimenez, Gustavo
    Donohue, Michael
    Gessert, Devon
    Harless, Kelly
    Salazar, Jennifer
    Cabrera, Yuliana
    Walter, Sarah
    Hergesheimer, Lindsey
    Harvey, Danielle
    Bernstein, Matthew
    Fox, Nick
    Thompson, Paul
    Schuff, Norbert
    DeCArli, Charles
    ALZHEIMERS & DEMENTIA, 2019, 15 (01) : 106 - 152
  • [7] Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics
    Ritter, Aaron
    Cummings, Jeffrey
    FRONTIERS IN NEUROLOGY, 2015, 6
  • [8] MCI and Alzheimer's disease
    Feldman, H.
    JOURNAL OF NEUROLOGY, 2008, 255 : 4 - 4
  • [9] Nitrate therapeutics: from nitroglycerin to clinical trials of a novel nitrate in Alzheimer's disease
    Thatcher, GRJ
    Bennett, BM
    Reynolds, JN
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2004, 11 (01): : 65 - 66
  • [10] Aducanumab for Alzheimer's disease: A regulatory perspective
    Nistico, Robert
    Borg, John Joseph
    PHARMACOLOGICAL RESEARCH, 2021, 171
12345